Skip to content
11 | 05 | 2023

LM® LLLT + OPE® IPL: Consistently Effective Together.


Light Modulation® LLLT technology has recently been studied in a piece of research in combination therapy with OPE® IPL tech.  

The retrospective, monocentric study carried out in the Ophthalmology Department at Brest University Hospital, evaluates the efficacy and tolerance of intense pulsed light (IPL) therapy with low‐level light therapy (LLLT), our patented photo-biomodulation technology, in the treatment of meibomian gland dysfunction (MGD) and more broadly ocular dryness, from both the subjective point of view of the patient, but also from the clinical point of view. 

A cohort of patients (37 subjects, 74 eyes) with MGD associated with keratitis (Oxford Score greater than or equal to 1) underwent the protocol of 3 eye-light® sessions 14 days apart at 1 month and 3 months after, between January 2019 and April 2020.  

The study, published on JFO, the Journal Français d’Ophtalmologie, by A.A. Benyoussef (MD), B. Cochener (MD, PhD) et al., has shown the clinical efficacy of combined therapy of intense pulsed light (OPE® IPL) with Low‑Level Light Therapy (LM® LLLT) in treating meibomian gland dysfunction (MGD). 
The study demonstrates a significant improvement of OSDI scores at 1 month (P<0.0001) and 3 months (P<0.0001). The SPEED score, TBUT, Oxford score, Meibomian gland atrophy and NIBUT were also statistically and significantly improved at 1 and 3 moths. 

Directly citing the conclusions of the paper: 

Treatment with the Eye-Light® in three sessions every two weeks significantly reduced symptoms and ocular surface damage in patients with MGD. This data suggests that the use of Eye-Light® may represent a good option for patients with MGD. 

BENYOUSSEF, A.-A.; ARZEL, F.; COCHENER, B. 3-month post-procedural evaluation of a combined intense pulsed light and photo-biomodulation system in the treatment of meibomian gland dysfunction. Journal Français d'Ophtalmologie, April 2023. 
> Link to Paper  
> Link to Full Bibliography 

For more information, see 


Espansione Group 

Press Office  

© 2023 Espansione Group, All Rights Reserved 
Posted on May 11th, 2023 in Newsroom 


Get Started Now
Get in touch to find out how you can benefit from the Espansione Ecosystem of Technologies and Solutions.

In compliance with current regulations, let us know which audience you belong to:

You must fill in the form to download the file.

I want to be updated about Espansione products and services

This field is required.
This field is required.
This field is required.
A valid email address is required.
This field is required.
This field is required.
I have read the privacy policy and the terms and conditions of the site
This field is required.
I want to be updated about Espansione products and services. You can unsubscribe at any time, by using the “unsubscribe” feature at the bottom of any communication you receive.

Thank you for contacting us.